UP!
 |
|
 Amgen headquarters in Thousand Oaks, California
|
|
|
Formerly called
|
Applied Molecular Genetics (1980–1983) |
|---|---|
|
Type
|
Public |
| Traded as | NASDAQ: AMGN NASDAQ-100 Component S&P 100 Component S&P 500 Component SEHK: 4332 |
| Industry | Biotechnology |
| Founded | 1980 |
| Headquarters | Thousand Oaks, California, U.S. |
|
Key people
|
Robert A. Bradway (Chairman, President, and CEO) |
| Products | Epogen, Aranesp, Kineret, Enbrel, Neulasta, Neupogen, Nplate, Vectibix, Prolia, Xgeva, and Sensipar/Mimpara. |
| Revenue |  US$22.99 billion (2016) |
|
Operating income
|
US$9.79 billion (2016) |
|
Net income
|
US$7.72 billion (2016) |
| Total assets | US$77.63 billion (2016) |
| Total equity | US$29.88 billion (2016) |
|
Number of employees
|
19,200 (December 2016) |
| Website | www |
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988, followed by Kevin W. Sharer in 2000. Robert A. Bradway became Amgen’s president and chief executive officer in May 2012 following Sharer's retirement.
The company has made at least five major corporate acquisitions.
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
Amgen
(Founded 1983 as Applied Molecular Genetics)
Synergen Inc
(Acq 1994)
Kinetix Pharmaceuticals Inc
(Acq 2000)
Immunex Corporation
(Acq 2002)
Tularik Inc (Acq 2004)
Abgenix Inc
(Acq 2006)
Avidia Inc
(Acq 2006)
Alantos Pharmaceuticals
(Acq 2007)
Ilypsa Inc
(Acq 2007)
Alantos Pharmaceuticals Holdings Inc
(Acq 2007)
BioVex Group Inc
(Acq 2011)
Laboratório Químico Farmacêutico Bergamo Ltda
(Acq 2011)
Micromet Inc
(Acq 2012)
Mustafa Nevzat İlaç
(Acq 2012)
KAI Pharmaceuticals
(Acq 2012)
deCODE genetics
(Acq 2012)
Onyx Pharmaceuticals
(Acq 2013)
NextCODE genetics
(Spun off 2013)
Dezima Pharma
(Acq 2015)
Catherex
(Acq 2015)
As of December, 2013, Amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions (conditions lists are highly generalized; see each article for more detail):
As of December 2013, Amgen had 11 drugs in Phase III clinical trials.
In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without. Later in the same week, the company (in conjunction with AstraZeneca) reported positive results for brodalumab in a phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.
In March 2015, the company announced it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.
In June 2015 Amgen presented Phase 2 clinical trial data for their anti-CGRP antibody AMG 334 for migraine.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q4 2022 | 2023-04-26 | Future report Set alerts | |
| Q3 2022 | 2022-11-03 | 4.70 | 4.70 |
| Q2 2022 | 2022-08-04 | 4.65 | 4.65 |
| Q1 2022 | 2022-04-27 | 4.25 | 4.25 |
| Q4 2021 | 2022-02-07 | 4.36 | 4.36 |
| Q3 2021 | 2021-11-02 | 4.67 | 4.67 |
| Q2 2021 | 2021-08-03 | 4.38 | 4.38 |
| Q1 2021 | 2021-04-27 | 3.70 | 3.70 |
| Q4 2020 | 2021-02-02 | 3.81 | 3.81 |
| Q3 2020 | 2020-10-28 | 4.37 | 4.37 |
| 2016-07-13 | Reiterated Rating | Bank of America Corp. | Hold | $182.00 |
| 2016-07-13 | Reiterated Rating | Jefferies Group | Buy | $187.00 |
| 2016-07-12 | Reiterated Rating | BMO Capital Markets | Buy | |
| 2016-06-29 | Initiated Coverage | Sanford C. Bernstein | Market Perform | $161.00 |
| 2016-06-29 | Reiterated Rating | Goldman Sachs | Buy | |
| 2016-06-29 | Reiterated Rating | Morgan Stanley | Overweight | |
| 2016-06-29 | Reiterated Rating | Goldman Sachs Group Inc. | Buy | |
| 2016-06-26 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-06-15 | Reiterated Rating | Goldman Sachs | Buy | $202.00 |
| 2016-06-09 | Reiterated Rating | Leerink Swann | Market Perform | $186.00 |
| 2016-06-09 | Reiterated Rating | BMO Capital Markets | Outperform | $186.00 |
| 2016-06-08 | Reiterated Rating | Bank of America | Hold | $182.00 |
| 2016-06-08 | Reiterated Rating | Bank of America Corp. | Hold | $182.00 |
| 2016-05-19 | Reiterated Rating | Bank of America | Hold | |
| 2016-05-19 | Reiterated Rating | Morgan Stanley | Buy | |
| 2016-05-18 | Reiterated Rating | RBC Capital | Buy | |
| 2016-05-18 | Reiterated Rating | Royal Bank Of Canada | Buy | |
| 2016-05-16 | Reiterated Rating | Robert W. Baird | Hold | |
| 2016-05-10 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-05-10 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
| 2016-05-01 | Reiterated Rating | Leerink Swann | Market Perform | $179.00 to $186.00 |
| 2016-04-30 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-04-30 | Reiterated Rating | BMO Capital Markets | Buy | $183.00 to $186.00 |
| 2016-04-29 | Reiterated Rating | Morgan Stanley | Buy | $195.00 |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-04-08 | Boost Price Target | Morgan Stanley | $193.00 to $195.00 | |
| 2016-04-05 | Initiated Coverage | BMO Capital Markets | Outperform | $183.00 |
| 2016-04-05 | Reiterated Rating | Leerink Swann | Market Perform | |
| 2016-03-29 | Reiterated Rating | Morgan Stanley | Overweight | $193.00 |
| 2016-03-16 | Reiterated Rating | RBC Capital | Buy | $190.00 |
| 2016-03-16 | Reiterated Rating | Piper Jaffray | Overweight | $191.00 |
| 2016-03-08 | Reiterated Rating | Cowen and Company | Outperform | $193.00 |
| 2016-03-03 | Reiterated Rating | Piper Jaffray | Buy | $200.00 to $191.00 |
| 2016-02-25 | Initiated Coverage | Citigroup Inc. | Neutral | $165.00 |
| 2016-02-23 | Reiterated Rating | BTIG Research | Sell | $135.00 |
| 2016-02-22 | Reiterated Rating | Cowen and Company | Outperform | $193.00 |
| 2016-02-22 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $165.00 |
| 2016-02-22 | Lower Price Target | Goldman Sachs | $218.00 to $201.00 | |
| 2016-02-11 | Reiterated Rating | Jefferies | Buy | $187.00 |
| 2016-02-11 | Reiterated Rating | Jefferies Group | Buy | $187.00 |
| 2016-02-08 | Lower Price Target | Argus | Buy | $202.00 to $185.00 |
| 2016-02-06 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-02-04 | Initiated Coverage | Leerink Swann | Market Perform | $179.00 |
| 2016-01-29 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-01-29 | Boost Price Target | Morgan Stanley | $189.00 to $193.00 | |
| 2016-01-29 | Lower Price Target | JPMorgan Chase & Co. | Neutral | $174.00 to $165.00 |
| 2016-01-29 | Boost Price Target | Goldman Sachs | $213.00 to $218.00 | |
| 2016-01-29 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-01-28 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-01-28 | Reiterated Rating | Piper Jaffray | Buy | $200.00 |
| 2016-01-28 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $174.00 to $165.00 |
| 2016-01-22 | Reiterated Rating | Wells Fargo | Hold | |
| 2016-01-22 | Reiterated Rating | Wells Fargo & Co. | Hold | |
| 2016-01-19 | Initiated Coverage | Credit Suisse | Outperform | $205.00 |
| 2016-01-13 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2016-01-09 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-01-08 | Reiterated Rating | Piper Jaffray | Buy | $200.00 |
| 2016-01-07 | Initiated Coverage | BTIG Research | Sell | $135.00 |
| 2015-12-18 | Initiated Coverage | Atlantic Securities | Overweight | $202.00 |
| 2015-12-14 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $160.00 to $193.00 |
| 2015-12-09 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $174.00 |
| 2015-12-04 | Initiated Coverage | Wells Fargo | Market Perform | |
| 2015-11-05 | Upgrade | Piper Jaffray | Overweight | |
| 2015-10-29 | Reiterated Rating | Piper Jaffray | Overweight | $200.00 |
| 2015-10-29 | Boost Price Target | Morgan Stanley | $160.00 | |
| 2015-10-29 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2015-10-12 | Reiterated Rating | Piper Jaffray | Overweight | $200.00 |
| 2015-09-22 | Reiterated Rating | Nomura | Buy | $190.00 to $191.00 |
| 2015-09-22 | Reiterated Rating | Nomura Holdings Inc. | Buy | $190.00 to $191.00 |
| 2015-09-02 | Reiterated Rating | Sanford C. Bernstein | Hold | |
| 2015-08-31 | Initiated Coverage | Raymond James | Market Perform | |
| 2015-08-31 | Initiated Coverage | Raymond James Financial Inc. | Market Perform | |
| 2015-08-28 | Reiterated Rating | Piper Jaffray | Buy | $200.00 |
| 2015-08-28 | Boost Price Target | Jefferies Group | Buy | $195.00 to $197.00 |
| 2015-08-17 | Reiterated Rating | Deutsche Bank | Buy | $195.00 |
| 2015-08-17 | Reiterated Rating | Deutsche Bank AG | Buy | $195.00 |
| 2015-08-14 | Reiterated Rating | RBC Capital | Outperform | $190.00 |
| 2015-08-12 | Reiterated Rating | Cowen and Company | Buy | $193.00 |
| 2015-07-31 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $174.00 |
| 2015-07-31 | Reiterated Rating | Cowen and Company | Outperform | $189.00 to $193.00 |
| 2015-07-31 | Boost Price Target | Piper Jaffray | Overweight | $200.00 |
| 2015-07-31 | Boost Price Target | Barclays | Equal Weight | $180.00 to $185.00 |
| 2015-07-31 | Reiterated Rating | Deutsche Bank | Buy | $192.00 to $195.00 |
| 2015-07-31 | Boost Price Target | Barclays PLC | Equal Weight | $180.00 to $185.00 |
| 2015-07-29 | Reiterated Rating | RBC Capital | Outperform | $185.00 to $190.00 |
| 2015-07-23 | Reiterated Rating | Piper Jaffray | Buy | $192.00 |
| 2015-06-25 | Reiterated Rating | Deutsche Bank | Buy | $192.00 |
| 2015-06-12 | Reiterated Rating | Nomura | Buy | $182.00 |
| 2015-06-11 | Reiterated Rating | Jefferies Group | Buy | $195.00 |
| 2015-06-11 | Reiterated Rating | Deutsche Bank | Buy | $192.00 |
| 2015-06-07 | Reiterated Rating | Cowen and Company | Outperform | $189.00 |
| 2015-06-03 | Reiterated Rating | Piper Jaffray | Overweight | $192.00 |
| 2015-05-28 | Lower Price Target | Deutsche Bank | Buy | $200.00 to $192.00 |
| 2015-05-27 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $160.00 |
| 2015-05-26 | Reiterated Rating | Morgan Stanley | Equal Weight | $179.00 to $171.00 |
| 2015-05-26 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $160.00 |
| 2015-05-09 | Reiterated Rating | Goldman Sachs | Buy | |
| 2015-05-08 | Set Price Target | Piper Jaffray | Buy | $192.00 |
| 2015-05-04 | Reiterated Rating | Bank of America | Neutral | |
| 2015-04-30 | Reiterated Rating | Piper Jaffray | Overweight | $192.00 |
| 2015-04-23 | Reiterated Rating | Barclays | Neutral to Equal Weight | |
| 2015-04-22 | Lower Price Target | Nomura | Buy | $194.00 to $191.00 |
| 2015-04-22 | Boost Price Target | Jefferies Group | Buy | $182.00 to $195.00 |
| 2015-04-22 | Boost Price Target | Leerink Swann | Buy | $187.00 |
| 2015-04-22 | Boost Price Target | RBC Capital | Outperform | $178.00 to $185.00 |
| 2015-04-16 | Reiterated Rating | Piper Jaffray | Overweight | $187.00 |
| 2015-03-23 | Set Price Target | Bank of America | Hold | $179.00 |
| 2015-03-19 | Reiterated Rating | Deutsche Bank | Buy | $195.00 |
| 2015-03-18 | Reiterated Rating | Piper Jaffray | Overweight | $187.00 |
| 2015-03-02 | Reiterated Rating | JPMorgan Chase & Co. | Hold | |
| 2015-03-02 | Reiterated Rating | Piper Jaffray | Overweight | $187.00 |
| 2015-02-13 | Set Price Target | Piper Jaffray | Buy | $187.00 |
| 2015-01-28 | Set Price Target | Credit Suisse | Hold | $180.00 |
| 2015-01-06 | Initiated Coverage | Barclays | Equal Weight | $180.00 |
| 2015-01-06 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $163.00 |
| 2015-01-05 | Boost Price Target | Nomura | $200.00 | |
| 2015-01-05 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $165.00 to $177.00 |
| 2014-12-17 | Boost Price Target | Deutsche Bank | $195.00 | |
| 2014-11-12 | Reiterated Rating | Deutsche Bank | Positive to Buy | $192.00 to $190.00 |
| 2014-10-29 | Boost Price Target | Argus | Buy | $140.00 to $185.00 |
| 2014-10-29 | Reiterated Rating | Citigroup Inc. | Buy | $162.00 to $185.00 |
| 2014-10-29 | Reiterated Rating | Credit Suisse | Neutral | $135.00 to $160.00 |
| 2014-10-29 | Upgrade | Nomura | Neutral to Buy | $144.00 to $193.00 |
| 2014-10-28 | Reiterated Rating | Jefferies Group | Buy | $142.00 to $172.00 |
| 2014-10-28 | Reiterated Rating | Nomura | Neutral to Buy | $193.00 to $144.00 |
| 2014-10-28 | Reiterated Rating | Deutsche Bank | Buy | $163.00 to $190.00 |
| 2014-10-28 | Boost Price Target | RBC Capital | Outperform | $150.00 to $165.00 |
| 2014-10-27 | Boost Price Target | Piper Jaffray | Overweight | $150.00 to $170.00 |
| 2014-10-01 | Initiated Coverage | Bank of America | Neutral | $152.00 |
| 2014-09-17 | Boost Price Target | Morgan Stanley | Overweight | $143.00 to $151.00 |
| 2014-09-08 | Reiterated | RBC Capital Mkts | Outperform | $138 to $150 |
| 2014-09-08 | Boost Price Target | RBC Capital | Outperform | $138.00 to $150.00 |
| 2014-09-02 | Boost Price Target | Leerink Swann | Market Perform | $140.00 to $153.00 |
| 2014-08-04 | Reiterated Rating | Argus | Buy | $135.00 to $140.00 |
| 2014-07-31 | Boost Price Target | Leerink Swann | $135.00 to $140.00 | |
| 2014-07-31 | Boost Price Target | Credit Suisse | $125.00 to $135.00 | |
| 2014-07-31 | Boost Price Target | Cowen and Company | $131.00 to $145.00 | |
| 2014-07-30 | Reiterated | RBC Capital Mkts | Outperform | $125 to $138 |
| 2014-07-30 | Reiterated Rating | Deutsche Bank | Buy | $149.00 to $160.00 |
| 2014-07-30 | Reiterated Rating | Nomura | Neutral | $129.00 to $142.00 |
| 2014-07-30 | Reiterated Rating | Citigroup Inc. | Buy | $155.00 to $159.00 |
| 2014-07-30 | Boost Price Target | BMO Capital Markets | $125.00 to $135.00 | |
| 2014-07-30 | Boost Price Target | RBC Capital | Outperform | $125.00 to $138.00 |
| 2014-07-18 | Boost Price Target | Deutsche Bank | Buy | $144.00 to $149.00 |
| 2014-06-10 | Reiterated Rating | Morgan Stanley | Overweight | $140.00 |
| 2014-05-12 | Reiterated Rating | Morgan Stanley | Overweight | $140.00 |
| 2014-05-12 | Reiterated Rating | Deutsche Bank | Buy | |
| 2014-04-23 | Boost Price Target | Oppenheimer | Market Perform | $121.00 to $122.00 |
| 2014-04-23 | Reiterated Rating | Jefferies Group | Buy | $145.00 to $142.00 |
| 2014-04-23 | Reiterated Rating | Deutsche Bank | Buy | $142.00 to $144.00 |
| 2014-04-23 | Boost Price Target | Nomura | Neutral | $129.00 |
| 2014-03-28 | Boost Price Target | Jefferies Group | Buy | $138.00 to $145.00 |
| 2014-03-26 | Initiated Coverage | Morgan Stanley | Overweight | $140.00 |
| 2014-03-21 | Boost Price Target | Barclays | Equal Weight | $115.00 to $130.00 |
| 2014-03-18 | Boost Price Target | Citigroup Inc. | Buy | $155.00 |
| 2014-01-31 | Boost Price Target | Argus | Buy | $130.00 to $135.00 |
| 2014-01-29 | Boost Price Target | Jefferies Group | $133.00 to $138.00 | |
| 2014-01-27 | Upgrade | Ned Davis Research | Neutral to Buy | |
| 2014-01-08 | Initiated Coverage | Nomura | Neutral | $131.00 |
| 2013-12-06 | Reiterated Rating | Citigroup Inc. | Buy | $139.00 to $131.00 |
| 2013-11-26 | Initiated Coverage | Piper Jaffray | Overweight | $143.00 |
| 2013-11-20 | Reiterated Rating | Deutsche Bank | Buy | $138.00 to $142.00 |
| 2013-11-18 | Reiterated Rating | Goldman Sachs | Conviction-Buy | $140.00 |
| 2013-11-07 | Reiterated Rating | Goldman Sachs | Conviction-Buy | $140.00 |
| 2013-10-23 | Boost Price Target | Brean Capital | Buy | $119.00 to $132.00 |
| 2013-10-22 | Reiterated Rating | Deutsche Bank | Buy | |
| 2013-10-02 | Reiterated Rating | Leerink Swann | Market Perform | $128.00 |
| 2013-09-24 | Boost Price Target | BMO Capital Markets | Market Perform | $108.00 to $116.00 |
| 2013-08-29 | Reiterated | UBS | Buy | $121 to $124 |
| 2013-08-27 | Reiterated | Barclays | Overweight | $105 to $115 |
| 2013-07-31 | Reiterated | Oppenheimer | Perform | $100 to $109 |
| 2013-04-08 | Reiterated | RBC Capital Mkts | Outperform | $95 to $105 |
| 2013-01-25 | Upgrade | Argus | Hold to Buy | $96 |
| 2013-01-24 | Reiterated | UBS | Buy | $96 to $98 |
| 2012-09-12 | Downgrade | Robert W. Baird | Outperform to Neutral | $84 |
| 2012-09-10 | Upgrade | UBS | Neutral to Buy | $80 to $96 |
| 2012-08-02 | Downgrade | Argus | Buy to Hold | |
| 2012-02-09 | Downgrade | Oppenheimer | Outperform to Perform | |
| 2011-09-09 | Downgrade | Standpoint Research | Buy to Hold | |
| 2011-05-10 | Reiterated | MP Advisors | Outperform | $63 to $65 |
| 2011-04-25 | Reiterated | Stifel Nicolaus | Buy | $70 to $68 |
| 2016-07-13 | Reiterated Rating | Bank of America Corp. | Hold | $182.00 |
| 2016-07-13 | Reiterated Rating | Jefferies Group | Buy | $187.00 |
| 2016-07-12 | Reiterated Rating | BMO Capital Markets | Buy | |
| 2016-06-29 | Initiated Coverage | Sanford C. Bernstein | Market Perform | $161.00 |
| 2016-06-29 | Reiterated Rating | Goldman Sachs | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AMGN 1317 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 47.46M |
| BlackRock Inc. | 46.87M |
| STATE STREET CORP | 29.07M |
| BlackRock Institutional Trust Company, N.A. | 21.08M |
| PRIMECAP MANAGEMENT CO/CA/ | 15.56M |
| BlackRock Fund Advisors | 14.59M |
| Capital Research Global Investors | 12.61M |
| MORGAN STANLEY | 11.78M |
| GEODE CAPITAL MANAGEMENT, LLC | 11.20M |
| SCHWAB CHARLES INVESTMENT MANAGEMENT INC | 9.24M |
| FMR LLC | 8.70M |
| GOLDMAN SACHS GROUP INC | 7.97M |
| WELLS FARGO & CO/MN | 7.56M |
| BlackRock Group LTD | 7.30M |
| NORTHERN TRUST CORP | 7.16M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| AMGEN INC | 0.07% (541399) | AMGN / TLOG / |
| Bradway Robert A Chairman, CEO and President | 0.06% (433413) | AMGN / BA / NSC / |
| Amgen Ventures LLC | 0.04% (334126) | AMGN / |
| HOOPER ANTHONY C EVP, Global Commercial Ops. | 0.03% (216030) | AMGN / |
| OMENN GILBERT S | 0.02% (180547) | AMGN / ESPR / GALT / |
| MCNAMEE BRIAN M EVP | 0.01% (102516) | AMGN / |
| Peacock Jonathan M EVP & CFO | 0.01% (94414) | AMGN / KITE / |
| SCOTT DAVID J SVP, Gen. Counsel & Secy. | 0.01% (93949) | AMGN / |
| Harper Sean E EVP, Research & Development | 0.01% (61296) | AMGN / |
| Meline David W EVP & CFO | 0.01% (60155) | AMGN / MMM / TRW / |
| HERRINGER FRANK C | 0.01% (50875) | AMGN / SCHW / SWY / |
| Graham Jonathan P SVP, Gen. Counsel & Secy. | 0.01% (47756) | AMGN / DHR / |
| COFFMAN VANCE D | 0.01% (43041) | AMGN / DE / MMM / |
| Michael A Kelly Acting CFO | 0.01% (39177) | AMGN / |
UM